Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2

JAMA Neurology

Volumn 70, Issue 10, 2013, Pages 1302-1304

  Tazen, Sirinan ^a   Figueroa, Karla ^b   Kwan, Justin Y ^c   Goldman, Jill ^a   Hunt, Ann ^d   Sampson, Jacinda ^a   Gutmann, Laurie ^e   Pulst, Stefan M ^b   Mitsumoto, Hiroshi ^a   Kuo, Sheng Han ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 2; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATAXIA; ATXN2 GENE; CAG REPEAT; CASE REPORT; COLOMBIA; COMORBIDITY; DISEASE DURATION; ELECTROMYOGRAPHY; FAMILY HISTORY; FAMILY STUDY; FEMALE; GAIT DISORDER; GENE; GENETIC ANALYSIS; HUMAN; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; SLURRED SPEECH; SPINOCEREBELLAR DEGENERATION; UNIVERSITY HOSPITAL;

EID: 84885818460     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.443     Document Type: Article

References (13)

1. Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type Nat Genet. 1996;14(3):269-276.
2. Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069-1075.
3. Lee T, Li YR, Ingre C, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet. 2011;20(9):1697-1700.
4. Corrado L, Mazzini L, Oggioni GD, et al. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum Genet. 2011;130(4):575-580.
5. Ross OA, Rutherford NJ, Baker M, et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet. 2011;20(16):3207-3212.
6. Daoud H, Belzil V, Martins S, et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol. 2011;68(6):739-742.
7. Van Damme P, Veldink JH, van Blitterswijk M, et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology. 2011;76(24):2066-2072.
8. Sorarù G, Clementi M, Forzan M, et al. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology. 2011;76(23):2030-2031.
9. Chen Y, Huang R, Yang Y, et al. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2011;32(10):e1-e5.
10. Gellera C, Ticozzi N, Pensato V, et al. ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? implication for genetic testing and counseling. Neurobiol Aging. 2012;33(8):e15-e21.
11. Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathol. 2012;124(2): 221-230.
12. Bonini NM, Gitler AD. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci. 2011;45(3):676-683.
13. Hart MP, Gitler AD. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci. 2012;32(27):9133-9142.